The mixed lymphocyte reaction (MLR) is a basic immunological assay used to study T cell responses to allogeneic antigens (from different individuals). By co-culturing peripheral blood mononuclear cells (PBMCs) from two genetically distinct donors, the MLR models the activation and proliferation of T cells in response to non-self antigens. This assay has become a critical tool for assessing immune compatibility, evaluating transplant rejection risk, and screening the immunomodulatory effects of therapeutic agents. This blog provides a comprehensive overview of the molecular mechanisms underlying the MLR, its distinctions from antigen-specific T cell activation, the predictive value of MLR for drug effects, methodological variations, evaluation assays, and its broad applications in drug discovery.
The Molecular Mechanism of an MLR
At the heart of the MLR is the interaction between T cell receptors (TCRs) on responder T cells and allogeneic major histocompatibility complex (MHC) molecules on stimulator cells. Unlike antigen-specific activation, where the TCR recognizes a specific peptide-MHC complex, the MLR relies on the ability of TCRs to bind to structurally distinct, non-self MHC molecules, often independent of the peptide presented. This interaction triggers a cascade of intracellular signaling events: the TCR complex, lacking intrinsic kinase activity, recruits the kinase Lck, which phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) on CD3 subunit of T cells. This leads to the activation of ZAP70 and subsequent downstream signaling, culminating in T cell activation, proliferation, and cytokine secretion. Both CD4+ and CD8+ T cells participate, producing cytokines such as IFN-γ, TNF-α, and IL-2, and upregulating activation markers like CD25.
Differences Between MLR Stimulation and Antigen-Specific T Cell Activation
The MLR is characterized by the phenomenon of alloreactivity, where a high frequency of T cells can respond to non-self MHC molecules due to cross-reactivity of their TCRs. This “direct allorecognition” is fundamentally different from antigen-specific activation, which requires the TCR to recognize a precise peptide presented by self-MHC, resulting in a much more selective immune response. In allorecognition, the TCR often focuses on polymorphic regions of the allogeneic MHC, sometimes with less dependence on the peptide. The kinetic segregation model describes how TCR-pMHC binding excludes large phosphatases like CD45, favoring kinase-driven signaling and T cell activation.
Can an MLR Accurately Predict Therapeutic Drug Effects on Antigen-Specific T Cell Activation?
The MLR is a robust and physiologically relevant assay for modeling T cell activation in response to allogeneic HLA antigens, making it valuable for drug screening, especially for immunomodulatory agents such as checkpoint inhibitors. It captures a broad range of T cell responses, including proliferation and cytokine production. However, its primary limitation is its lack of antigen specificity; it measures general allo-responsiveness rather than responses to defined peptide antigens. Some drugs may also require modified MLR protocols to reveal their effects, particularly when the expression of relevant ligands is transient. For drugs targeting antigen-specific T cell activation, more targeted assays are necessary. Thus, while the MLR is invaluable for screening and characterizing immunotherapies affecting broad T cell functions, its results must be interpreted within the context of its allogeneic nature.
Methods Used for Mixed Lymphocyte Reaction and Their Applications
There are several methodological variations of the MLR, each suited to different experimental goals. The one-way MLR involves inactivating stimulator cells, enabling unidirectional measurement of responder cell proliferation, and is particularly useful for potency assays due to its reproducibility and control. The two-way MLR allows both donor populations to respond, providing a comprehensive measure of allogeneic immune responses. Using purified T cells or dendritic cells enables detailed study of specific cell interactions and is ideal for mechanism-of-action studies by providing the necessary specificity to dissect drug effects on cellular pathways.
Whole PBMC MLRs reflect the complexity of the immune system, while proliferation assays using labeled markers allow precise quantification of cell division.
Example of Different MLR Methods
| Method | Key Feature | Best Use Case |
| One-way MLR | Only responder cells proliferate | Potency assays, specific immune response |
| Two-way MLR | Both populations respond | General allogeneic response, transplantation |
| Purified T cells in MLR | Isolates T cell response | Mechanism-of-action, T cell-focused studies |
| PBMCs in MLR | Full immune context | Broad immunogenicity, complex interactions |
| Labeled proliferation assays in MLR | Quantitative cell division measurement | Potency, comparison of immune stimulants |
Assays to Evaluate T Cell Responses in MLR Methods
Several assays are commonly used to evaluate T cell responses in mixed MLR setups. Each assay provides different types of information about T cell activation, proliferation, cytokine production, and phenotypic changes. Below is a comparison of the main assays:
T Cell Proliferation Assays
- Description: Measure the division of T cells in response to allogeneic stimulation. Commonly performed using [3H]-thymidine incorporation, BrdU, or dye dilution methods (e.g., CFSE [carboxyfluorescein diacetate succinimidyl ester], CellTrace).
- Strengths: Direct, quantitative measurement of T cell activation; high throughput possible.
- Limitations: Does not provide information on functional phenotype or cytokine production.
Cytokine ELISA / Multiplex Cytokine Assays
- Description: Detect and quantify cytokines (e.g., IFN-γ, IL-2, TNF-α) secreted into the culture supernatant by activated T cells using ELISA or bead-based multiplex platforms with Flow Cytometry.
- Strengths: Sensitive, quantitative, and allows multiplexing for several cytokines at once.
- Limitations: Measures cumulative cytokine production from all cells in the well; cannot distinguish which cell subset produced which cytokine.
Intracellular Cytokine Staining
- Description: Uses flow cytometry to detect cytokines within individual T cells after short-term restimulation and fixation/permeabilization.
- Strengths: Allows identification of cytokine-producing cells at the single-cell level and can be combined with surface marker analysis.
- Limitations: Requires cell fixation; only provides a snapshot at the time of analysis.
Detection of Activation-Specific Cell Surface Markers by Flow Cytometry
- Description: Measures upregulation of activation markers such as CD25, CD69, CD71, HLA-DR, and immune checkpoints (PD-1, CTLA-4) on T cells.
- Strengths: Multiparametric; can simultaneously assess activation, differentiation, and exhaustion phenotypes.
- Limitations: Surface marker expression may not always correlate with functional activity.
Classes of Therapeutic Drugs Affecting T Cells Tested in Mixed Lymphocyte Reaction (MLR)
Various classes of therapeutic drugs that modulate T cell function can be assessed using the MLR. Examples are listed below.
Immune Checkpoint Inhibitors
These drugs block inhibitory pathways that normally regulate T cell activation, thus enhancing T cell responses.
Examples:
- Anti-PD-1 antibodies (e.g., Pembrolizumab, Nivolumab)
- Anti-PD-L1 antibodies (e.g., Atezolizumab)
- Anti-CTLA-4 antibodies (e.g., Ipilimumab)
Immunosuppressive Agents
These drugs suppress T cell activation and proliferation, commonly used in transplantation and autoimmune diseases.
Examples:
- Calcineurin inhibitors (e.g., Tacrolimus, Cyclosporine)
- mTOR inhibitors (e.g., Sirolimus)
- Corticosteroids (e.g., Dexamethasone, Prednisolone)
Immunomodulatory Drugs
These agents can modulate T cell responses through various mechanisms, including altering cytokine production or T cell differentiation.
Examples:
- Lenalidomide (immunomodulatory effects, used in hematologic malignancies)
- Galunisertib (TGF-β receptor-1 inhibitor)
- Sulfavant A (TREM2 agonist, modulates dendritic cell and T cell interaction)
Cytokine Modulators and Biologics
Drugs that target cytokines or their receptors, affecting T cell activation and differentiation.
Examples:
- Anti-IL-2 receptor antibodies (e.g., Basiliximab)
- Anti-IL-6 receptor antibodies (e.g., Tocilizumab)
Experimental and Small Molecule Agents
Novel compounds or small molecules under investigation for their effects on T cell function.
Examples:
- Protein synthesis inhibitors (used in research to modulate T cell responses in MLR)
Conclusion
The mixed lymphocyte reaction remains a cornerstone assay in immunology and drug discovery, offering a physiologically relevant platform to assess T cell responses to allogeneic antigens. Its molecular basis, methodological flexibility, and broad applicability make it indispensable for evaluating immunomodulatory drugs, understanding mechanisms of action, and predicting therapeutic efficacy and safety. While it does not directly assess antigen-specific responses, the MLR provides critical insights into general T cell alloreactivity and the immunomodulatory potential of new therapies, ensuring its continued relevance in both research and clinical development.
Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.
About Marin Biologic Laboratories
Our Recent Publication/Meeting Presentation on Gene Therapy
1. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1
3. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.
Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise
With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.
Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.
Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories
Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)
Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)
- ADME/Tox
- Molecular Biology
- The Art of Cell Culture
- Exosomes
- Stability Services
- Potency Assay
- Gene Therapy Assays
- Immunotherapy Assays
- Antiviral Therapy Assays
- cGMP
- MLR
- Cell Based Assays
- ELISA
- Flow Cytometry
- Protein
- PCR-qPCR
- Immunoassay
- Radioimmunoassay
- GLP
- Transfection
- Cell Therapy Assays
- Targeted Protein Degradation
- Research to Commercialization
